One emerging class of agents for double-refractory is the non-covalent BTKi (e.g., Pirto), which demonstrate efficacy in covalent-BTKi-resistant CLL harboring secondary C481 BTK mutations [69–71]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.